LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

To be considered for this study, you would generally need to be an adult between 18 and 75 years old.

You must have been diagnosed with acquired blepharoptosis, which means your eyelids have started to droop, specifically in both eyes. The doctors will measure the amount of droop in your eyelid (called MRD1), and it needs to be within a specific range to qualify. It's also important that your eyesight is reasonably good (20/80 or better) in both eyes.

Beyond these medical requirements, you need to be able to understand and sign the consent form to show you agree to take part. Also, you must feel that your droopy eyelids bother you enough to want treatment for them. There are also specific rules about contraception for both men and women if they are able to have children, to ensure safety during the study.

If you join the study, you'll first have a screening visit to check if you meet all the requirements. If you do, you'll return for a second visit within 8 days. At this visit, you'll be given either the new eye drops or the dummy drops. Neither you nor the study team will know which you're receiving.

You will use the assigned eye drops twice a day for 6 weeks. There will be study visits at 2 weeks and 6 weeks to see how you're doing and to check for any side effects. On some specific visit days, you'll take your morning or afternoon dose at the clinic, and on other days you'll take it at home. Two weeks after you finish using the eye drops, you'll have one final follow-up visit. The total time you'd be involved in the study from start to finish would be around 8-9 weeks.